Abdominal discomfort is a common side effect of isradipine.

Isradipine is a substrate CYP 3A4. It is also a week inhibitor of CYP 3A4, but it is not a mechanism- based inhibitor.

Dihydropyridine calcium antagonist.

Isradipine is used in the treatment of essential hypertension.

Isradipine is a substrate of CYP3A4. At least 6 biologically inactive metabolites have been identified and mainly consist of mono acids of the pyridine derivative and a cyclic lactone product (Micromedex). In an in vitro study isradipine was found to be a week competitive inhibitor (Wang 1999). The results of an in -vivo study indicate that isradipine is not a clinically significant inhibitor of CYP3A4 in humans (Beckman 1999) and the SPC also states that isradipine does not seem to inhibit the cytochrome P450 enzymes, in particular CYP3A4, to a clinically significant extent.

Uneventful use reported in one patient (C. Andersson).

Uneventful use reported in 1 patient with acute porphyria.